Loading...

We've got a brand new version of Simply Wall St! Try it out

Chuang Yi Biotech

GTSM:6566
Snowflake Description

Adequate balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6566
GTSM
NT$456M
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

Chuang Yi Biotech Co., ltd. engages in the research, development, and marketing of medicines and health foods in Taiwan. The last earnings update was 96 days ago. More info.


Add to Portfolio Compare Print
  • Chuang Yi Biotech has significant price volatility in the past 3 months.
6566 Share Price and Events
7 Day Returns
-4.1%
GTSM:6566
-1.7%
TW Pharmaceuticals
-0.5%
TW Market
1 Year Returns
-20.3%
GTSM:6566
16%
TW Pharmaceuticals
17.7%
TW Market
6566 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Chuang Yi Biotech (6566) -4.1% 0.6% -13.7% -20.3% -50.4% -
TW Pharmaceuticals -1.7% 3.4% 3.5% 16% -10.7% -23.2%
TW Market -0.5% 2.8% 9.1% 17.7% 26.3% 26.1%
1 Year Return vs Industry and Market
  • 6566 underperformed the Pharmaceuticals industry which returned 16% over the past year.
  • 6566 underperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
6566
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Chuang Yi Biotech's competitors could be found in our database.

6566 Value

 Is Chuang Yi Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Chuang Yi Biotech to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Chuang Yi Biotech.

GTSM:6566 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 7.9%
Perpetual Growth Rate 10-Year TW Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for GTSM:6566
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.687 (1 + (1- 20%) (19.26%))
0.862
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.86
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.862 * 5.96%)
7.86%

Discounted Cash Flow Calculation for GTSM:6566 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Chuang Yi Biotech is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

GTSM:6566 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (TWD, Millions) Source Present Value
Discounted (@ 7.86%)
2020 14.41 Est @ 55.66% 13.36
2021 20.14 Est @ 39.78% 17.31
2022 25.91 Est @ 28.67% 20.65
2023 31.32 Est @ 20.89% 23.14
2024 36.16 Est @ 15.44% 24.77
2025 40.37 Est @ 11.63% 25.63
2026 43.98 Est @ 8.96% 25.89
2027 47.10 Est @ 7.09% 25.70
2028 49.82 Est @ 5.78% 25.21
2029 52.25 Est @ 4.87% 24.51
Present value of next 10 years cash flows NT$226.00
GTSM:6566 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= NT$52.25 × (1 + 2.73%) ÷ (7.86% – 2.73%)
NT$1,045.26
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= NT$1,045.26 ÷ (1 + 7.86%)10
NT$490.26
GTSM:6566 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= NT$226.00 + NT$490.26
NT$716.26
Equity Value per Share
(TWD)
= Total value / Shares Outstanding
= NT$716.26 / 22.97
NT$31.18
GTSM:6566 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$31.18
Current discount Discount to share price of NT$19.84
= -1 x (NT$19.84 - NT$31.18) / NT$31.18
36.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Chuang Yi Biotech is available for.
Intrinsic value
36%
Share price is NT$19.84 vs Future cash flow value of NT$31.18
Current Discount Checks
For Chuang Yi Biotech to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Chuang Yi Biotech's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Chuang Yi Biotech's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Chuang Yi Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Chuang Yi Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:6566 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in TWD NT$0.07
GTSM:6566 Share Price ** GTSM (2019-11-18) in TWD NT$19.84
Taiwan, Province of China Pharmaceuticals Industry PE Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 22.23x
Taiwan, Province of China Market PE Ratio Median Figure of 1,423 Publicly-Listed Companies 16.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Chuang Yi Biotech.

GTSM:6566 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:6566 Share Price ÷ EPS (both in TWD)

= 19.84 ÷ 0.07

303.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Chuang Yi Biotech is overvalued based on earnings compared to the TW Pharmaceuticals industry average.
  • Chuang Yi Biotech is overvalued based on earnings compared to the Taiwan, Province of China market.
Price based on expected Growth
Does Chuang Yi Biotech's expected growth come at a high price?
Raw Data
GTSM:6566 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 303.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Taiwan, Province of China Pharmaceuticals Industry PEG Ratio Median Figure of 5 Publicly-Listed Pharmaceuticals Companies 0.89x
Taiwan, Province of China Market PEG Ratio Median Figure of 247 Publicly-Listed Companies 1.07x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Chuang Yi Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Chuang Yi Biotech's assets?
Raw Data
GTSM:6566 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in TWD NT$9.21
GTSM:6566 Share Price * GTSM (2019-11-18) in TWD NT$19.84
Taiwan, Province of China Pharmaceuticals Industry PB Ratio Median Figure of 45 Publicly-Listed Pharmaceuticals Companies 2.17x
Taiwan, Province of China Market PB Ratio Median Figure of 1,936 Publicly-Listed Companies 1.44x
GTSM:6566 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:6566 Share Price ÷ Book Value per Share (both in TWD)

= 19.84 ÷ 9.21

2.15x

* Primary Listing of Chuang Yi Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Chuang Yi Biotech is good value based on assets compared to the TW Pharmaceuticals industry average.
X
Value checks
We assess Chuang Yi Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Chuang Yi Biotech has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

6566 Future Performance

 How is Chuang Yi Biotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Chuang Yi Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.8%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Chuang Yi Biotech expected to grow at an attractive rate?
  • Unable to compare Chuang Yi Biotech's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Chuang Yi Biotech's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
  • Unable to compare Chuang Yi Biotech's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:6566 Future Growth Rates Data Sources
Data Point Source Value (per year)
Taiwan, Province of China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 11.8%
Taiwan, Province of China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 20.2%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:6566 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:6566 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-06-30 312 15 2
2019-03-31 324 12 -1
2018-12-31 336 9 -3
2018-09-30 331 -25 6
2018-06-30 325 -59 15
2018-03-31 283 -59 10
2017-12-31 241 -58 4
2017-09-30 168 -59 -24
2017-06-30 94 -60 -52
2017-03-31 95 -54 -48
2016-12-31 96 -48 -44
2016-09-30 98 -47 -43

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Chuang Yi Biotech is high growth as no earnings estimate data is available.
  • Unable to determine if Chuang Yi Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:6566 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Chuang Yi Biotech Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6566 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-06-30 0.07
2019-03-31 -0.03
2018-12-31 -0.13
2018-09-30 0.26
2018-06-30 0.65
2018-03-31 0.41
2017-12-31 0.18
2017-09-30 -1.05
2017-06-30 -2.31
2017-03-31 -2.19
2016-12-31 -2.08
2016-09-30 -2.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Chuang Yi Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Chuang Yi Biotech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Chuang Yi Biotech's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Chuang Yi Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Chuang Yi Biotech has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

6566 Past Performance

  How has Chuang Yi Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Chuang Yi Biotech's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Chuang Yi Biotech has delivered over 20% year on year earnings growth in the past 5 years.
  • Chuang Yi Biotech's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Chuang Yi Biotech's 1-year earnings growth is negative, it can't be compared to the TW Pharmaceuticals industry average.
Earnings and Revenue History
Chuang Yi Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Chuang Yi Biotech Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6566 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 311.50 1.50 144.84 13.52
2019-03-31 323.93 -0.69 153.09 14.14
2018-12-31 336.36 -2.89 161.34 14.76
2018-09-30 330.61 6.05 156.71 13.88
2018-06-30 324.86 14.98 152.08 13.00
2018-03-31 283.01 9.50 135.18 15.20
2017-12-31 241.15 4.02 118.27 17.40
2017-09-30 167.65 -23.93 110.55 19.23
2017-06-30 94.16 -51.88 102.83 21.06
2017-03-31 95.21 -47.97 100.19 18.40
2016-12-31 96.26 -44.06 97.56 15.73
2016-09-30 98.49 -42.70 95.18 16.93
2016-06-30 100.71 -41.34 92.81 18.12
2016-03-31 97.59 -37.97 87.08 18.76
2015-12-31 94.46 -34.59 81.34 19.40
2014-12-31 104.65 -17.74 83.79 3.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Chuang Yi Biotech has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Chuang Yi Biotech used its assets less efficiently than the TW Pharmaceuticals industry average last year based on Return on Assets.
  • Chuang Yi Biotech has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Chuang Yi Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Chuang Yi Biotech has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

6566 Health

 How is Chuang Yi Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Chuang Yi Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Chuang Yi Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Chuang Yi Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Chuang Yi Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Chuang Yi Biotech Company Filings, last reported 4 months ago.

GTSM:6566 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 211.59 81.03 83.29
2019-03-31 211.59 81.03 83.29
2018-12-31 229.35 63.49 106.41
2018-09-30 229.35 63.49 106.41
2018-06-30 210.14 44.04 52.69
2018-03-31 210.14 44.04 52.69
2017-12-31 232.41 80.64 120.99
2017-09-30 232.41 80.64 120.99
2017-06-30 195.11 0.00 80.40
2017-03-31 195.11 0.00 80.40
2016-12-31 228.43 0.00 121.08
2016-09-30 228.43 0.00 121.08
2016-06-30 147.23 0.00 41.71
2016-03-31 147.23 0.00 41.71
2015-12-31 172.77 0.00 75.04
2014-12-31 167.45 0.00 70.54
  • Chuang Yi Biotech's level of debt (38.3%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Chuang Yi Biotech's debt level has increased without past 5-year debt data.
  • Debt is not well covered by operating cash flow (19%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 10.5x coverage).
X
Financial health checks
We assess Chuang Yi Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Chuang Yi Biotech has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

6566 Dividends

 What is Chuang Yi Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Chuang Yi Biotech dividends.
If you bought NT$2,000 of Chuang Yi Biotech shares you are expected to receive NT$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Chuang Yi Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Chuang Yi Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:6566 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1323 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Chuang Yi Biotech has not reported any payouts.
  • Unable to verify if Chuang Yi Biotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Chuang Yi Biotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Chuang Yi Biotech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Chuang Yi Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Chuang Yi Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Chuang Yi Biotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

6566 Management

 What is the CEO of Chuang Yi Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Chuang Yi Biotech has no CEO, or we have no data on them.
Management Team

Sophie Juan

TITLE
Director of Finance & Accounting
TENURE
0.5 yrs

Tai Hong Chen

TITLE
Head of the Direct Selling Operations
TENURE
7.9 yrs
Board of Directors Tenure

Average tenure of the Chuang Yi Biotech board of directors in years:

0.5
Average Tenure
  • The average tenure for the Chuang Yi Biotech board of directors is less than 3 years, this suggests a new board.
Board of Directors

Robbin Shih

TITLE
Chairman
TENURE
0.3 yrs

Jacky Wang

TITLE
Director

Wen Hua Zhang

TITLE
Director

Jun Hui Zhang

TITLE
Director

Wan Zheng

TITLE
Director

Jin Jin Zhang

TITLE
Director

Jyun Jhang

TITLE
Director
TENURE
0.5 yrs

Wann Cheng

TITLE
Director
TENURE
0.5 yrs

Rui-Wen Wu

TITLE
Member of the Supervisory Committee

Bao Ji Wu

TITLE
Member of the Supervisory Committee
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess Chuang Yi Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Chuang Yi Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

6566 News

Simply Wall St News

6566 Company Info

Description

Chuang Yi Biotech Co., ltd. engages in the research, development, and marketing of medicines and health foods in Taiwan. It offers products in the areas of gastrointestinal, metabolism, and general health care, as well as allergy reducing products. The company was founded in 2011 and is based in Taipei City, Taiwan.

Details
Name: Chuang Yi Biotech co., ltd.
6566
Exchange: GTSM
Founded: 2011
NT$455,764,480
22,972,000
Website: http://www.cybiotech.com.tw
Address: Chuang Yi Biotech co., ltd.
No.3-1, Park Street,
3F.-1,
Taipei City,
115,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 6566 Common Stock Taipei Exchange TW TWD 20. Jan 2016
Number of employees
Current staff
Staff numbers
58
Chuang Yi Biotech employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 15:47
End of day share price update: 2019/11/18 00:00
Last earnings filing: 2019/08/14
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.